New biomarkers in T-cell lymphomas

详细信息    查看全文

• 作者：Bettina Bisig ; MD ; PhD^a ; ^b ; ¹ ; ^{bettina.bisig@ulg.ac.be} (Senior Resident in Pathology) ; Philippe Gaulard ; MD^c ; ^d ; ^e ; ² ; ^{philippe.gaulard@hmn.aphp.fr} (Full Professor of Pathology ; Research Director) ; Laurence de Leval ; MD ; PhD^b ; ^f ; ^{laurence.deleval@chuv.ch} (Full Professor of Pathology ; Head of Clinical Pathology)
• 关键词：peripheral T-cell lymphomas ; biomarkers ; translocations ; gene expression profiling ; targeted therapy ; prognosis
• 刊名：Best Practice Research Clinical Haematology
• 出版年：2012
• 出版时间：March, 2012
• 年：2012
• 卷：25
• 期：1
• 页码：13-28
• 全文大小：359 K

文摘

Peripheral T-cell lymphomas (PTCLs) are heterogeneous and uncommon malignancies characterized by an aggressive clinical course and a mostly poor outcome with current treatment strategies. The recent genome-wide molecular characterization of several entities has provided novel insights into their pathobiology and led to the identification of new biomarkers with diagnostic, prognostic or therapeutic implications for PTCL patients. Cell lineage and differentiation antigens (markers of ¦Ã¦Ä or NK lineage, of cytotoxicity, of follicular helper T cells) reflect the tumour¡¯s biological behaviour, and their detection in tissue samples may refine the diagnostic and prognostic stratification of the patients. Previously unrecognized gene rearrangements are being discovered (ITK-SYK translocation, IRF4/MUM1 and DUSP22 rearrangements), and may serve as diagnostic genetic markers. Deregulated molecules within oncogenic pathways (NF-¦ÊB, Syk, PDGFR¦Á) and immunoreactive cell-surface antigens (CD30, CD52) have been brought to the fore as potential targets for guiding the development of novel therapies.